JAN 3 0 2006

Under the Personal Requestor of of

PTO/SB/122 (01-06)
Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CHANGE OF CORRESPONDENCE ADDRESS Application

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Application Number	10/635,807		
Filing Date	August 5, 2003		
First Named Inventor	Edward Rubenstein		
Art Unit	3761 Conf. 9762		
Examiner Name	Patricia Bianco		
Attorney Docket Number	11026/20072		

Please change the Correspondence Address for the above-identified patent application to:					
The address associated with Customer Number:	03000		•		
OR			·		
Firm or Individual Name					
Address					
City	Sta	te	Zip		
Country					
Telephone		Email			
This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).					
I am the:					
Applicant/Inventor					
	Assignee of record of the entire interest. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).				
Attorney or agent of reco	Attorney or agent of record. Registration Number				
Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number					
Signature					
Typed or Printed / GARY A. GRE	ENE				
Date January 27, 2006		ephone 215-567			
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.					
*Total offorms are submitted.					

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT Customer No. 03000 Attorney Docket No. I1026/20072

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicant(s): RUBENSTEIN, E., et al.

Group Art Unit: 3762

Serial No.: 10/635,807

Filing Date: August 5, 2003

Examiner: Patricia M. Bianco

Confirmation No.: 9762

For: INTERNALLY POWERED CSF PUMP SYSTEMS AND METHODS

REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Integra LifeSciences Corporation, the Assignee of the entire right, title and interest in the above-identified patent as specified in the accompanying Statement Under 37 CFR 3.73(b), hereby revokes all prior powers of attorney and appoints the attorneys at United States Patent and Trademark Office Customer No. 03000 as attorneys of record with full power of substitution and revocation to prosecute the patent and all continuations and divisions thereof, and to transact all business in the Patent and Trademark Office, including the payment of maintenance fees for patent(s) issuing on the application and its progeny.

Please change the correspondence address for the above-identified patent to Customer No. 03000 (Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., 1635 Market Street, 11th Floor – Seven Penn Center, Philadelphia, PA 19103-2212).

and the fax

The telephone number of **Customer No. 03000** is (215) 567-2010 and the fax number is (215) 751-1142.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

INTEGRA LIFESCIENCES CORPORATION

Date: 12/20/05

John B. Henneman III, Executive Vice President

JAN 3 0 2006

PATENT Customer No. 03000 Attorney Docket No. 11026/20072

3 Opp

THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicant(s): RUBENSTEIN, E., et al.

Group Art Unit: 3762

Serial No.: 10/635,807

Filing Date: August 5, 2003

Examiner: Patricia M. Bianco

Confirmation No.: 9762

For: INTERNALLY POWERED CSF PUMP SYSTEMS AND METHODS

STATEMENT UNDER 37 CFR 3.73(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The Assignee of the entire right, title and interest hereby seeks to take action in the Patent and Trademark Office in this matter.

IDENTIFICATION OF ASSIGNEE

Integra LifeSciences Corporation (A Delaware Corporation) 311 C Enterprise Drive Plainsboro, NJ 08436

PERSON AUTHORIZED TO SIGN

I, John B. Henneman III, represent that I am the Executive Vice President of Integra LifeSciences Corporation, and aver that I am empowered to sign this statement on behalf of the Assignee.



BASIS OF ASSIGNEE'S INTEREST

All right, title and interest in and to Application Serial No. 10/635,807 were transferred from the current assignee from the inventor as shown in the chain of title COP below and as recorded with the Patent and Trademark Office.

From: Edward Rubenstein (Filed with Appln. 08/05/2003) 1.

David L. Karshmer Elliott C. Levinthal Jaime S. Vargas Tom A. Saul

Eunoe, Inc. To:

Recorded: Reel/Frame:

2. From: Eunoe, Inc.

> Integra LifeSciences Corporation To:

Recorded: 10/12/2005 Reel/Frame: 016636/0253

DECLARATIONS

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of any patent issuing thereon.

INTEGRA LIFESCIENCES/CORPORATION

Date: 12/20/05

John B. Henneman III, Executive Vice President